Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. | No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited ...

For many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...

The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...

Germany’s Merck KGaA has appointed three new members to its executive board, which it says is a natural evolution in the company’s leadership as it continues to implement its growth strategy.

Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea’s CryptoMap platform.

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.

I really believe we have something that has a lot of unique features.” Merck KGaA had been developing the drug with partner Avillion and van Amstel’s team got in touch as soon as they heard ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...